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Poster Session II 107are females, two males. The mean age is 42(26–60) and the mean
follow-up is 7 (3–9) years. Although tumours have not been de-
scribed in this group of donors, nevertheless the G-CSF administra-
tion in patients with Multiple Sclerosis has been frequently
correlated with a worsening of the clinical status (2,3). Moreover,
the G-CSF therapy seems to exacerbate the recurrence of autoim-
mune diseases, as described in other published surveys (4).
Taken together, these data seem to confirm and underline the
need of a long-term clinical and haematological surveillance period
of healthy subjects stimulated with G-CSF. Nevertheless, the sur-
veillance duration has not been definitely fixed: ten years of follow-
up could be a too short period to lead to significant information on
the potential induction or enhancement of pathological conditions.
Bibliography: (1): Bone Marrow Transplantation, 36: 289–294,
2005; (2): Neurology, 54: 2147–2150, 2000; (3): J Neuroimmunol,
2006; (4): Bone Marrow Transplantotion 2001; 28: 1–12.
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IMPACT OF LONGITUDINAL LONG TERM TRANSPLANT CLINIC (LTTC)
ON SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANT (SCT)
Jagasia, M.1, Clifton, C.1, Vaughan, L.A.1, Chinratanalab, W.1,
Chen, H.2, Dixon, S.1, Hunt, C.1, Kassim, A.1. 1Vanderbilt University
Medical Center, Nashville, TN; 2Vanderbilt University Medical Center,
Nashville, TN.
Introduction: Allogeneic SCT patients (pts.) are followed inten-
sively for 100 days after SCT at the transplant center (TC). The
ideal model of follow-up after day 100 is not well studied. Pts. are
often transitioned back to their primary hematologist at the TC
(or in community). We hypothesized that a longitudinal LTTC su-
pervised by transplant physicians and mid-level providers and care
coordinated with consultants in other disciplines would improve
outcome. Methods: We established LTTC in 1/2006. All pts. after
allogeneic SCT (.day 100) were transitioned to LTTC (group[G]
1: transition day\120). Some pts. were transitioned after day 120 or
were referred by their primary hematologist to LTTC (G2). G3 was
a historical group of pts. with survival of at least 150 days after SCT
(care provided by primary hematologist). Overall survival (OS) was
measured from transition to LTTC for G1 and 2 and from day 150
for G3. Results: G 1, 2 and 3 had 43, 31 and 114 pts., respectively.
Groups were comparable for age at SCT, donor status, and disease
risk (CIBMTR definition). More pts. in G3 (74%) had ablative SCT
compared to G1 (51%) and G2 (65%) (P5 0.019). Median follow-
up time was different (G1: 349 days, G2: 966 days, G3: 765 days, P
\0.0001). Median OS was 1905 days (95% CI 1143–2664). The OS
for the 3 groups were different (P5 0.001). 1-yr. OS for G 1, 2 and 3
were 80%, 88%, and 59%. There were 4, 2, and 55 deaths in the 3
groups (non-relapse mortality: 0%, 50%, and 37%). In univariate
analyses (G1 1 2 vs.3), donor type (P 5 0.045), risk status (P 5
0.0012) and group status based on LTTC (time dependent variable)
(P 5 0.0478) were significant predictors of OS. Using Cox-regres-
sion analyses (adjusted for transplant age, donor type, transplant
type), risk status (low vs. high risk) (HR 2.82, P 5 0.0005) and
LTTC status (HR 1.97, P 5 0.047) were significant predictors of
OS. Using Cox-regression analyses (G1 vs. 3) risk status (low vs.
high risk) (HR 2.74, P 5 0.0012) and LTTC status (HR 3.27, P
5 0.0251) were significant predictors of OS.Conclusion:Although
limited by retrospective nature, short follow up in G1 and compar-
ision to a historical control, our study shows that pts. followed in the
LTTC clinic with coordinated care from consultants had a better
OS compared with pts. who were followed prior to LTTC being es-
tablished. The impact of LTTC clinic on other long-term trans-
plant problems (viz. diabetes, dyslipidemias, osteoporosis, sexual
dysfunction) will be studied.
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PRE-TRANSPLANT SEUM C-PEPTIDE LEVEL PREDICTS FOR POST-
TRANSPLANT DIABETES MELLITUS (PTDM) AFTER ALLOGENEIC STEM
CELL TRANSPLANT (SCT)
Jagasia, S.1, Perkins, J.1, Survant, M.1, Chen, H.2, Jagasia, M.3. 1Van-
derbilt Univeristy Medical Center, Nashville, TN; 2Vanderbilt Univer-
isty Medical Center, Nashville, TN; 3Vanderbilt Univeristy Medical
Center, Nashville, TN.The incidence of new onset PTDM after an allogeneic SCT is un-
known. We conducted a prospective study in patients (pts.) undergo-
ing allogeneic SCT with cyclosporine based graft-versus-host
disease (GVHD) prophylaxis to identify risk factors for PTDM.
Methods: Non diabetic pts. meeting screening criteria were en-
rolled. Demographics including family history, race, past history
of transient diabetes and body-mass index were obtained. Baseline
fasting samples included blood glucose (BG), lipid profile, serum
fructosamine, serum C-peptide and insulin. Pts. had weekly fasting
BG. PTDM was defined by standard criteria. Systemic steroids
(SS) were used to treat GVHD. Results: Median age of pts. (20
males, 17 females) was 43 yrs. (range, 21–66). Median FBG was
97 mg/dL (range, 80–119). 22 of 37 pts. (60%) developed DM at
a median of 41 days post SCT (range, 8–93). 14 of 37 pts (38%)
completed study until day 100 without developing DM and 1 pa-
tient died prior to day 100 without PTDM. In univariate analyses,
the only pre-transplant variable that predicted for PTDM was se-
rum C-peptide and serum insulin levels. Pts. with PTDM had
higher pre-transplant serum C-peptide level compared to pts. with-
out PTDM (4.68, 95% CI 3.76 to 5.66 vs. 2.29, 95% CI 1.87 to
2.71, P\0.0001). Pts. with PTDM had higher mean pre-transplant
serum insulin level compared to pts. without PTDM (22.86, 95%
CI 16.44 to 29.33 vs. 10.57, 95% CI 6.64 to 14, P\ 0.0001). 13
of 21 (61%) pts. who received SS developed PTDM compared
with 9 of 16 (56%) who did not receive SS (P 5 0.729). In a multi-
variable Cox-regression analyses (adjusted for SS use), C-peptide
was an independent predictor of PTDM (HR 1.264; 95% CI
1.06–1.50, P 5 0.008). The interaction between C-peptide and SS
was significant. In subgroup analyses of pts. without SS, C-peptide
had a HR of 1.89 (95% CI 1.16–3.06, P5 0.009), and in pts. with SS
the HR was 1.15 (95% CI 0.94–1.4, P 5 0.161). Conclusion: Our
study shows that PTDM occurs in 60% of pts. after allogeneic SCT
and in 56% of pts. without SS use. Pre-transplant C-peptide level is
an independent risk factor, especially in patients without SS use.
The exact etiology of PTDM in pts. without SS use is not known.
Perhaps, a pre-transplant higher C-peptide level identifies patients
at risk for metabolic stress following allogeneic SCT. It is well es-
tablished that elevated C-peptide and insulin levels are hallmark fea-
tures of insulin resistant states and early type 2 diabetes.291
COMPARISON OF OUTCOMES IN CHILDREN UNDERGOING A SINGLE AL-
LOGENEIC TRANSPLANT USING BONE MARROW (BM) OR UMBILICAL
CORD BLOOD (UCB) AS STEM CELL SOURCE. THE CHILDREN’S MEMO-
RIAL HOSPITAL EXPERIENCE
Merchant, M.1, Huang, W.1, Kletzel, M.1,2. 1Children’s Memorial Hos-
pital, Chicago, IL; 2Northwestern University Feinberg School of Medi-
cine, Chicago, IL.
Objective: To evaluate differences in transplant outcomes be-
tween recipients of BM and UCB. Method: We evaluate 137 trans-
plants with BM and 119 UCB at Children’s Memorial Hospital,
between 1992 and 2007. BM: 122 MR, 15 MUD; 108 pts (78.8%)
had malignancies (ALL n 5 55, AML n 5 31, others n 5 22),
46% were in first complete remission (CR1), 28.5% in $ CR 2,
and 8% in partial remission (PR). 29 (21.2%) had non-malignant
conditions (THAL 5 7, Aplastic Anemia 5 8, SCIDS 5 2, others
5 12). 67.9% received myeloablative conditioning (fTBI, VP-Cy,
or Thiotepa); 32.1% had reduced intensity conditioning (RIC)
(VP/Cy, Bu/FLU/, 6 ATG). 52 female, 85 male; age 9.2 yrs (0.2–
23); weight 30.4 kg (4–85.1). HLA matching, 6/6 (100), 5/6 (28),
4/6 (9). Median TNC infused was 1.96  108/kg, 1.22  108/kg
MNC, 7.45 106/kg CD34. UCB: 82 pts (68.9%) had malignancies
(ALL n5 40, AML n5 24, others n5 18), 36.1% in CR1, 25.2% in
$CR2, 7.6% in PR. 37 pts (31.1%) had non-malignant conditions
(SCIDS n5 11, THAL n5 3, Aplastic Anemia n5 2, others5 21).
79% received myeloablation (fTBI/VP/Cy for malignancies, fTBI/
CY 6Thiotepa for non-malignant); 21% had RIC (VP/Cy or Bu/
FLU/6 ATG). 53 female, 66 male; age 5.4 yrs (0.1–20.6), weight
15.7 kg (4–73). HLA matching 6/6 (12) 5/6 (29) 4/6 (70) 3/6 (8).
Cell dose infused was 0.8  108/kg TNC, 0.55  108/kg MNC,
0.78  06/kg CD34. Result/Outcome: BM: 86.3% achieved
ANC (.500 cells/mL), 88.4% achieved PLT count (.20,000
cells/mL) at median of 18.3 days (10–71) and 32.9 days (4–222)
108 Poster Session IIresp. 23 pts (16.8%) died from transplant related mortality
(TRM)(d1 100). 20 pts (14.6%) had relapse at 132 days from trans-
plant (6–1097). 53.3% pts developed acute GVHD, 17.5% chronic
GVHD. 75 pts (54.7%) are event free survivors (EFS) with median
f/u of 3234 days. Overall Survival (OS) is 52.9% with f/u of 896
days. UCB: 67.6% achieved ANC, 62.1% achieved PLT at median
of 26 days (14–62) and 46 days (14–105) resp. 26 pts (21.8%) died
from TRM. 19 pts (16%) had relapse in 53 days (21–503). 54.6%
had acute GVHD, 9.2% had chronic GVHD. 65 (54.6%) are
EFS at present with f/u of 1967 days and OS is 52.2% with f/u of
769 days. Conclusion: Patients undergoing a single allogeneic
transplant with BM or UCB, show no statistical difference in
TRM, Relapse, EFS, OS or acute GVHD. A statistically significant
difference was found in age, infused cells dose, time to engraftment
and in chronic GVHD. UCB patients were younger, received lower
cell dose and have less chronic GVHD.Transplant Characteristics & Outcomes
BM UCB p valuePatient
Age (years) 9.2 ± 0.4 5.4 ± 0.4 \0.0001Cell Dose
dose CD34  106/kg 1.5 ± 0.1 0.7 ± 0.05 \0.0001
TNC  108/kg 2.7 ± 0.1 0.8 ± 0.06 \0.0001Outcome Measures
ANC .500 cells/mL
(days)18.3 ± 0.8 22.3 ± 0.8 0.0014PLT .20,000 cells/mL
(days)32.9 ± 3.3 46.5 ± 2.4 0.0026TRM % 16.8 21.8 not significant
Relapse % 14.6 16 not significant
EFS % 54.7 54.6 not significant
OS % 52.9 52.2 not significant
Acute GVHD % 53.3 54.6 not significant
Chronic GVHD % 17.5 9.2 0.03292
TRIPLE POSTGRAFTING IMMUNOSUPPRESSION FAILS TO PREVENT
GRAFT REJECTION IN DOGS GIVEN DLA-IDENTICAL MARROWS AFTER
1 GY TOTAL BODY IRRADIATION (TBI)
Sorror, M.1, Leisenring, W.1,3, Mielcarek, M.1,2, Baron, F.1,
Diaconescu, R.1, Hogan,W.1, Graves, S.1, Storb, R.1,2. 1Fred Hutchinson
Cancer Research Center; 2University of Washington; 3University of
Washington.
We investigated in a canine model whether combining three
postgrafting immunosuppressive drugs averted late graft rejection
after conditioning with 1 Gy of TBI, which was consistently seen
in historical dogs given two drugs. Sixteen dogs were given four dif-
ferent three-drug combinations after 1Gy TBI and DLA-identical
marrow grafts (Table). All 16 dogs showed initial engraftment.
Thirteen dogs rejected their grafts after a median duration of donor
chimerism of 9 weeks, while 3 dogs had sustained grafts for .26
weeks. The 3 dogs with durable mixed chimerism had received a me-
dian number of 6.14  108 nucleated marrow cells/kg compared to
3.6 108/kg given to the 13 dogs with rejection (p5 0.03). To con-
firm this finding, we constructed Cox regression model including
the 16 current dogs and 16 historical dogs receiving 1 Gy TBI
and given dual immunosuppression. After adjusting for immuno-
suppressive regimens received, each increase of 1 108/kg of nucle-
ated marrow cell doses decreased the hazard of rejection by 0.5 (p5
0.003). We also assessed the effects of TBI doses of 2.0 and 1.0 Gy
on immune functions in 2 dogs each which were not given marrow
grafts. The mean nadirs among dogs given 2 Gy versus 1 Gy TBI
were 376 versus 753 cells/ml, respectively. Statistically significant re-
ductions in CD3 and CD4 nadirs (p\ 0.001 for all), but not CD8
nadirs (p5 0.38), at day 14 were observed in dogs given 2Gy versus
1 Gy TBI. Moreover, the lymph node contents of CD3, CD4, and
CD8 cells were significantly lower in dogs given 2 Gy TBI com-
pared to 1 Gy TBI (p\ 0.001 for all). One functional assay used,
lymphocyte proliferation in response to DLA-mismatched stimula-tor cells, failed to show clear differences between dogs given either 2
Gy or 1 Gy TBI. An in-vivo functional assay, B-cell and T-cell de-
pendent production of IgM and IgG antibodies in response to sheep
red blood cell injections, showed a trend and statistically significant
greater suppressions of IgM and IgG antibody formation (p 5 0.08
and 0.008, respectively) after 2 Gy compared to 1 Gy TBI. Overall,
triple postgrafting immunosuppression after 1 Gy TBI was well tol-
erated but failed to prevent graft rejection in this model. In-vivo ra-
diation studies have shown higher numbers of remaining host
lymphocytes and better T-cell dependent antibody production after
1Gy compared to 2 Gy TBI. Transplanting larger number of donor
marrow cells might improve the rate of engraftment after 1 Gy TBI
Table. Marrow grafts from DLA-identical littermates/siblings after




















recoveryGroup 1MMF, 10 mg/kg
bid SC on days
0 to 27
G199 3.8 5 5 Yes 9 Yes1 CSP, 10 mg/kg
bid orally on
days - 1 to 35
G217 3.6 56 17 Yes 12 Yes1 SRL, 0.05
mg/kg once
daily SC on
days 0 to 27
G246 4.04 3 55 Yes 9 YesG284 3.6 20 14 Yes 20 YesG286 5.1 15 10 Yes 12 YesGroup 2MMF, 10 mg/kg
bid SC on
days 0 to 27
G234 5.71 50 40 Yes 9 Yes1 CSP, 15 mg/kg
bid orally on
days - 1 to 35
G274 2.5 25 15 Yes 7 Yes1 MTX, 0.4
mg/kg IV on
days 1, 3, 6, and 11
G244 7.98 65 50 No .26 NoG283 2.78 14 10 Yes 9 YesG225 3.63 50 35 Yes 11 YesGroup 3MTX, 0.4 mg/kg
IV on days 1, 3,
6, and 11
G367 5.43 10 8 Yes 9 Yes1 CSP, 10 mg/kg
bid orally on
days - 1 to 35
G432 3 71 57 Yes 11 Yes1 SRL, 0.05
mg/kg once
daily SC on
days 0 to 27
G424 5.75 38 31 No .26 NoGroup 4MMF, 10 mg/kg
bid SC on days
0 to 41 followed
by a 20% taper
per week
until day 69
G359 1.76 15 13 Yes 9 Yes1 CSP, 10 mg/kg
bid orally on
days - 1 to 27
G391 1.47 15 14 Yes 14 Yes1 SRL, 0.05
mg/kg once daily
SC on days 0 to
41 followed by a
20% taper per
week until day 69
G247 4.7 55 30 No .26 NoCSP indicates cyclosporine; MMF, mycophenolate mofetil; SRL, si-
rolimus; MTX, methotrexate; PBMC, peripheral blood mononu-
clear cells; BID, twice daily; PO, orally; and SC, subcutaneously.
